A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Trial Profile

A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Ivacaftor (Primary) ; Tezacaftor (Primary) ; VX 152 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2017 Results published in the Vertex Pharmaceuticals media release.
    • 08 Jan 2017 According to a Vertex Pharmaceuticals media release, the first data from this trial are expected in the second half of 2017.
    • 30 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top